A Convergence-Based Framework for Cancer Drug Resistance

被引：179

作者：

Konieczkowski, David J. ^{[1
]}

Johannessen, Cory M. ^{[2
]}

Garraway, Levi A. ^{[3
]}

机构：

[1] Harvard Radiat Oncol Program, Boston, MA 02114 USA

[2] Broad Inst, Cambridge, MA 02142 USA

[3] Eli Lilly & Co, Indianapolis, IN 46225 USA

来源：

CANCER CELL | 2018年 / 33卷 / 05期

关键词：

CELL LUNG-CANCER; METASTATIC BREAST-CANCER; NEUROENDOCRINE PROSTATE-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; BRAF INHIBITOR RESISTANCE; ANDROGEN-RECEPTOR GENE; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; TARGETED THERAPY; RAF INHIBITION;

D O I：

10.1016/j.ccell.2018.03.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite advances in cancer biology and therapeutics, drug resistance remains problematic. Resistance is often multifactorial, heterogeneous, and prone to undersampling. Nonetheless, many individual mechanisms of targeted therapy resistance may coalesce into a smaller number of convergences, including pathway reactivation (downstream re-engagement of original effectors), pathway bypass (recruitment of a parallel pathway converging on the same downstream output), and pathway indifference (development of a cellular state independent of the initial therapeutic target). Similar convergences may also underpin immunotherapy resistance. Such parsimonious, convergence-based frameworks may help explain resistance across tumor types and therapeutic categories and may also suggest strategies to overcome it.

引用

页码：801 / 815

页数：15

共 173 条

[31] Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade [J].

Cooper, Zachary A. ;

Juneja, Vikram R. ;

Sage, Peter T. ;

Frederick, Dennie T. ;

Piris, Adriano ;

Mitra, Devarati ;

Lo, Jennifer A. ;

Hodi, Stephen ;

Freeman, Gordon J. ;

Bosenberg, Marcus W. ;

McMahon, Martin ;

Flaherty, Keith T. ;

Fisher, David E. ;

Sharpe, Arlene H. ;

Wargo, Jennifer A. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (07) :643-654

[32] EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib [J].

Corcoran, Ryan B. ;

Ebi, Hiromichi ;

Turke, Alexa B. ;

Coffee, Erin M. ;

Nishino, Michiya ;

Cogdill, Alexandria P. ;

Brown, Ronald D. ;

Della Pelle, Patricia ;

Dias-Santagata, Dora ;

Hung, Kenneth E. ;

Flaherty, Keith T. ;

Piris, Adriano ;

Wargo, Jennifer A. ;

Settleman, Jeffrey ;

Mino-Kenudson, Mari ;

Engelman, Jeffrey A. .

CANCER DISCOVERY, 2012, 2 (03) :227-235

[33] Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance [J].

Das Thakur, Meghna ;

Salangsang, Fernando ;

Landman, Allison S. ;

Sellers, William R. ;

Pryer, Nancy K. ;

Levesque, Mitchell P. ;

Dummer, Reinhard ;

McMahon, Martin ;

Stuart, Darrin D. .

NATURE, 2013, 494 (7436) :251-255

[34] Secondary mutations as mediators of resistance to targeted therapy in leukemia [J].

Daver, Naval ;

Cortes, Jorge ;

Ravandi, Farhad ;

Patel, Keyur P. ;

Burger, Jan A. ;

Konopleva, Marina ;

Kantarjian, Hagop .

BLOOD, 2015, 125 (21) :3236-3245

[35] Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].

Di Nicolantonio, Federica ;

Martini, Miriam ;

Molinari, Francesca ;

Sartore-Bianchi, Andrea ;

Arena, Sabrina ;

Saletti, Piercarlo ;

De Dosso, Sara ;

Mazzucchelli, Luca ;

Frattini, Milo ;

Siena, Salvatore ;

Bardelli, Alberto .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712

[36] The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers [J].

Diaz, Luis A., Jr. ;

Williams, Richard T. ;

Wu, Jian ;

Kinde, Isaac ;

Hecht, J. Randolph ;

Berlin, Jordan ;

Allen, Benjamin ;

Bozic, Ivana ;

Reiter, Johannes G. ;

Nowak, Martin A. ;

Kinzler, Kenneth W. ;

Oliner, Kelly S. ;

Vogelstein, Bert .

NATURE, 2012, 486 (7404) :537-540

[37] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].

Douillard, Jean-Yves ;

Oliner, Kelly S. ;

Siena, Salvatore ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyorgy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean Luc ;

Rother, Mark ;

Williams, Richard ;

Rong, Alan ;

Wiezorek, Jeffrey ;

Sidhu, Roger ;

Patterson, Scott D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034

[38] Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras [J].

Dumaz, N ;

Marais, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :29819-29823

[39] In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling [J].

Dumaz, Nicolas ;

Hayward, Robert ;

Martin, Jan ;

Ogilvie, Lesley ;

Hedley, Douglas ;

Curtin, John A. ;

Bastian, Boris C. ;

Springer, Caroline ;

Marais, Richard .

CANCER RESEARCH, 2006, 66 (19) :9483-9491

[40] Resistance to therapy caused by intragenic deletion in BRCA2 [J].

Edwards, Stacey L. ;

Brough, Rachel ;

Lord, Christopher J. ;

Natrajan, Rachael ;

Vatcheva, Radost ;

Levine, Douglas A. ;

Boyd, Jeff ;

Reis-Filho, Jorge S. ;

Ashworth, Alan .

NATURE, 2008, 451 (7182) :1111-U8

← 1 2 3 4 5 6 7 8 9 10 →